Synergism of melflufen with immunotherapy, an anti-CD38 monoclonal antibody daratumumab, in patients with relapsed/refractory MM, is currently under investigation in clinical trials (Oriol et al., 2020; Mateos et al., 2020). Here, CD38 is linked to Miyoshi myopathy.